/HOTH
HOTH Stock - Hoth Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.09+1.87%
+$0.02 (+1.87%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.21
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.94
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.20
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HOTH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.08 – $1.10
TARGET (TP)$1.25
STOP LOSS$1.00
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.65
52W High$3.80
52W Low$0.66
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-8,215,432 | $-7,692,242 | $-11,065,554 | $-14,101,440 | $-7,301,974 |
| Net Income | $-8,188,300 | $-7,845,390 | $-11,371,953 | $-14,313,705 | $-7,197,816 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.28 | $-2.30 | $-9.50 | $-16.03 | $-14.56 |
Company Overview
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HOTHBeat Rate
53%
Last 19 quarters
Avg Surprise
+4.0%
EPS vs Estimate
Beats / Misses
10/6
3 met exactly
Latest EPS
$-0.30
Q4 2025
EPS Surprise History
Q1 24
+39.2%
$-0.31vs$-0.51
Q2 24
-7.0%
$-0.46vs$-0.43
Q3 24
+38.5%
$-0.24vs$-0.39
Q4 24
-3.3%
$-0.31vs$-0.30
Q1 25
+17.9%
$-0.32vs$-0.39
Q2 25
+20.6%
$-0.27vs$-0.34
Q3 25
+37.0%
$-0.17vs$-0.27
Q4 25
0.0%
$-0.30vs$-0.30
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.30 | $-0.30 | 0.0% | = MET |
Q3 2025 | Aug 12, 2025 | $-0.27 | $-0.17 | +37.0% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.34 | $-0.27 | +20.6% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-0.39 | $-0.32 | +17.9% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.30 | $-0.31 | -3.3% | ✗ MISS |
Q3 2024 | Aug 9, 2024 | $-0.39 | $-0.24 | +38.5% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.43 | $-0.46 | -7.0% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.51 | $-0.31 | +39.2% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.72 | $-0.60 | +16.7% | ✓ BEAT |
Q3 2023 | Aug 11, 2023 | $-1.16 | $-0.57 | +50.9% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.86 | $-0.88 | -2.3% | ✗ MISS |
Q1 2023 | Mar 31, 2023 | $-2.29 | $-2.72 | -18.8% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-2.39 | $-2.05 | +14.2% | ✓ BEAT |
Q3 2022 | Aug 12, 2022 | $-2.25 | $-2.25 | 0.0% | = MET |
Q2 2022 | May 12, 2022 | $-2.75 | $-2.75 | 0.0% | = MET |
Q1 2022 | Mar 30, 2022 | $-3.00 | $-3.50 | -16.7% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-3.75 | $-3.50 | +6.7% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-4.50 | $-3.50 | +22.2% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-2.50 | $-6.00 | -140.0% | ✗ MISS |
Latest News
D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Dec 4, 2025, 05:50 PM
Hoth Therapeutics Reports Pipeline Progress Across HT‑001, HT‑KIT, HT‑ALZ And New GDNF Program, Expands IP Portfolio And Partnerships
📈 PositiveBenzinga•Dec 3, 2025, 07:04 PM
HOTH stock has given up its prior gain. Hoth Therapeutics shares were trading higher after the company was accepted into the NVIDIA Connect program to expand its AI and accelerated computing capabilities.
➖ NeutralBenzinga•Nov 20, 2025, 03:30 PM•Also:
Hoth Therapeutics shares are trading higher after the company was accepted into the NVIDIA Connect program to expand its AI and accelerated computing capabilities.
📈 PositiveBenzinga•Nov 20, 2025, 01:15 PM•Also:
Hoth Therapeutics Joins NVIDIA Connect Program To Accelerate AI-Driven Drug Development
📈 PositiveBenzinga•Nov 20, 2025, 01:14 PM•Also:
D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Nov 17, 2025, 01:11 PM
Hoth Therapeutics Initiates U.S. Department Of VA–Backed Study Evaluating Potential Of Glial Cell Line–Derived Neurotrophic Factor As Novel Therapy For Obesity And Fatty Liver Disease
📈 PositiveBenzinga•Oct 27, 2025, 11:50 AM
Hoth Therapeutics reports FDA Orphan Drug designation for HT-KIT
📈 PositiveSeeking Alpha•Oct 21, 2025, 12:35 PM
Hoth Therapeutics shares are trading higher after the company announced FDA Orphan Drug designation and preclinical data for HT-KIT in rare C-KIT-driven cancers
📈 PositiveBenzinga•Oct 21, 2025, 12:28 PM
Hoth Therapeutics Announces Its Precision Antisense Oligonucleotide HT-KIT Receives FDA Orphan Drug Designation And New Preclinical Data Show HT-KIT Achieves Over 80% Suppression Of Kit Expression And Significant Tumor-Volume Reduction By Day 8 In Systemic Mastocytosis And GIST Models
📈 PositiveBenzinga•Oct 21, 2025, 12:26 PM
Hoth Therapeutics Expands Its AI Initiative Through Nvidia AI Enterprise Subscription License
📈 PositiveBenzinga•Oct 8, 2025, 02:24 PM•Also:
Hoth Therapeutics To Present HT-001 And HT-KIT Oncology Programs At BIO-Europe 2025
➖ NeutralBenzinga•Oct 7, 2025, 12:00 PM
Hoth Therapeutics Expands Intellectual Property Portfolio For HT-001 With New U.S. Provisional Patent Filings Covering Novel Dermatological Indications
📈 PositiveBenzinga•Sep 24, 2025, 12:16 PM
Hoth Therapeutics Provides Shareholder Update, Highlights Clinical Progress And Crypto Treasury Reserve Expansion
📈 PositiveBenzinga•Sep 16, 2025, 12:15 PM
Hoth Therapeutics Approves Expansion Of Treasury Reserve Strategy To Include Ethereum And Solana; May Purchase Up To $1M In Bitcoin, Ethereum And/or Solana As A Treasury Reserve Asset
📈 PositiveBenzinga•Sep 12, 2025, 12:28 PM•Also: , ,
Hoth Therapeutics Submits CTA To EMA To Expand Ongoing Phase II Trial Of HT-001, Topical Therapeutic For Skin Toxicities Associated With EGFRi
📈 PositiveBenzinga•Sep 10, 2025, 12:32 PM
Hoth Therapeutics shares are trading higher after the company reported its antisense therapy demonstrated efficacy against KIT-driven cancers.
📈 PositiveBenzinga•Sep 2, 2025, 12:22 PM
EXCLUSIVE: Hoth Therapeutics Tells Benzinga Co's Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity And GLP-Validated Bioanalytical Results, Says Exceeding Regulatory Standards
📈 PositiveBenzinga•Sep 2, 2025, 11:44 AM
D. Boral Capital Maintains Buy on Hoth Therapeutics, Maintains $5 Price Target
📈 PositiveBenzinga•Aug 18, 2025, 11:25 AM
Frequently Asked Questions about HOTH
What is HOTH's current stock price?
Hoth Therapeutics, Inc. (HOTH) is currently trading at $1.09 per share. The stock has moved +1.87% today.
What is the analyst price target for HOTH?
No analyst price targets are currently available for this stock.
What sector is Hoth Therapeutics, Inc. in?
Hoth Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is HOTH's market cap?
Hoth Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does HOTH pay dividends?
No, Hoth Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASBP
Aspire Biopharma Holdings, Inc.
$0.10
Mkt Cap: $0.0B
BCTX
BriaCell Therapeutics Corp.
$8.95
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
DARE
Daré Bioscience, Inc.
$2.09
Mkt Cap: $0.0B
ENTO
Entero Therapeutics, Inc.
$1.98
Mkt Cap: $0.0B
FBLG
FibroBiologics, Inc. Common Stock
$0.26
Mkt Cap: $0.0B
LEXX
Lexaria Bioscience Corp.
$0.58
Mkt Cap: $0.0B
PALI
Palisade Bio, Inc.
$1.83
Mkt Cap: $0.3B
PCSA
Processa Pharmaceuticals, Inc.
$3.78
Mkt Cap: $0.0B
PULM
Pulmatrix, Inc.
$2.37
Mkt Cap: $0.0B
Explore stocks similar to HOTH for comparison